StemCell Therapy

Item 1.01 Entry into a Material Definitive Agreement.

On October 29, 2021, the Company entered into an Exchange Agreement (the"Exchange Agreement") with shareholders who were issued shares under (i) variousconsulting and employment agreements during 2021 (the "Service Providers"), and(ii) those shareholders who were issued shares of common stock pursuant to theCompany's Management and Consultants Performance Stock Plan (the "MCP Plan")(each person who received shares pursuant to the MCP Plan is referred to as an"MCP Plan Holder").

The Service Providers who executed the Exchange Agreement were issued a total of30,300,000 shares under their respective consulting or employment agreements(the "Service Provider Shares"), and the MCP Plan Holders who executed theExchange Agreement received a total of 49,500,000 shares under the MCP Plan, foran aggregate of 79,800,000 shares of common stock. As of the effective date ofthe Agreement, the Service Providers and MCP Plan Holders who executed theExchange Agreement agreed to exchange their respective Service Provider Sharesor the shares issued under the MCP Plan for newly issued shares pursuant to theCompany's newly formed 2021 Equity Incentive Plan (the "EIP"), on a 1:1 basis,resulting in the issuance of 79,800,000 shares of common stock under the EIP(the "Exchange Shares").

The Exchange Agreement contains certain customary representations, warranties,and covenants for transactions of this type.

The description of the Exchange Agreement does not purport to be complete and isqualified in its entirety by reference to the full text of the form of ExchangeAgreement which is attached as Exhibit 10.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The disclosure set forth above in Item 1.01 of this Current Report on Form 8-Kwith respect to the issuances of the Exchange Sharers pursuant to the ExchangeAgreement is incorporated by reference into this Item 3.02.

The Exchange Shares were issued in reliance on the exemption from registrationrequirements thereof provided by Section 4(a)(2) of the Securities Act.

Item 9.01 Financial Statements and Exhibits.

* Schedules, exhibits and similar attachments have been omitted pursuant to Item601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies ofsuch omitted materials supplementally upon request by the U.S. Securities andExchange Commission.

1

Edgar Online, source Glimpses

See original here:
ORGANICELL REGENERATIVE MEDICINE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and...

This entry was posted on November 7, 2021 at 1:52 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |